Vyleesi What to Expect, Week-by-Week First Month

What Bremelanotide Is and How It Works

Bremelanotide targets the melanocortin system in the central nervous system rather than hormonal or vascular pathways. It binds melanocortin receptors MC3R and MC4R, modulating dopamine and serotonin signaling in areas linked to sexual motivation. The FDA label for bremelanotide describes the mechanism as "unknown" at a precise circuit level, but the MC4R pathway's role in sexual behavior is well-documented in pharmacology literature.

How It Differs from Flibanserin

Flibanserin (Addyi) must be taken daily as a 100 mg oral tablet regardless of planned sexual activity. Bremelanotide is dosed on demand, injected roughly 45 minutes before sex. That single structural difference changes the tolerability profile substantially. Daily dosing accumulates side-effect burden; as-needed dosing does not. A 2020 comparative review in CNS Drugs noted that on-demand dosing with bremelanotide may be preferred by women who want situational rather than continuous pharmacologic support.

Receptor Pharmacology

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. Its half-life is approximately 2.7 hours. Peak plasma concentration arrives around 1 hour post-injection, which is why the 45-minute pre-activity window exists. The pharmacokinetic data from the FDA submission confirm linear kinetics with no significant accumulation across repeated doses within recommended monthly limits.

The RECONNECT Trials: What the Data Actually Show

The RECONNECT program comprised two identical phase 3 randomized controlled trials. Combined, they enrolled 1,247 premenopausal women with a confirmed HSDD diagnosis. Both trials ran for 24 weeks of treatment, with the 8-week mark as the primary endpoint assessment.

Primary Efficacy Outcomes

Published in Obstetrics and Gynecology (2019), the pooled RECONNECT results showed that bremelanotide-treated women had a statistically significant increase in satisfying sexual events (SSEs) compared to placebo (P<0.001). The Female Sexual Function Index desire domain score improved by a mean of 0.36 points more than placebo. The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score fell by 11.1 points in the bremelanotide group versus 8.9 points in the placebo group, a difference that reached statistical significance.

These are modest absolute numbers. As the RECONNECT authors write directly: "The clinical meaningfulness of these differences should be considered in the context of the overall benefit-risk profile of bremelanotide for each individual patient." That phrasing reflects a real tension: statistically significant does not always translate into dramatic subjective change for every user.

Responder Rates

Approximately 25% of bremelanotide-treated women met the threshold for a clinically meaningful response in FSDS-DAO score, compared to roughly 17% on placebo. For SSEs, 35% of the bremelanotide group reported at least one additional satisfying event per month beyond baseline, versus 22% of placebo. The full published trial data on PubMed provide these subgroup breakdowns.

What RECONNECT Did Not Measure

The trials did not track subjective libido on a continuous daily basis, so the week-by-week experience described below draws from pharmacokinetic modeling, the adverse event timeline data in the FDA prescribing information, and post-marketing clinician reports.

Week-by-Week First Month: What to Expect

The timeline below organizes what is pharmacologically and clinically documented across weeks 1 through 4.

Week 1: First Injection and Side-Effect Calibration

The dominant experience of week 1 is side-effect management, not libido change. Nausea is the most common adverse event, affecting approximately 40% of women in RECONNECT. It typically begins 30 to 60 minutes post-injection and resolves within 1 to 2 hours in most cases. Taking the injection on an empty stomach worsens nausea; a light meal 2 hours before injection may reduce severity, though this has not been formally studied in a controlled fashion.

Flushing occurs in about 20% of users, presenting as warmth across the face, neck, and chest. The FDA label documents a transient blood pressure rise averaging 6 mmHg systolic and 3 mmHg diastolic, peaking at approximately 12 minutes and resolving by 12 hours. For women with no cardiovascular risk factors, this transient shift is clinically benign. For anyone with a history of cardiovascular disease, bremelanotide is contraindicated per FDA labeling.

Headache affects roughly 11% of users in week 1. Injection site bruising or redness occurs in about 17% but is usually self-limiting. Most women do not notice any change in desire during week 1. The CNS mechanism takes repeated receptor engagement to produce perceptible behavioral shifts in most patients, similar to how repeated administration of any centrally acting agent builds a clinical effect over time.

Week 2: Tolerability Improves for Many Users

By the second week of use, nausea tends to decrease in frequency and severity for women who continue. A 2019 tolerability analysis embedded in the RECONNECT data shows that nausea rates dropped significantly after the first two doses for continued users. Some women do not tolerate the nausea and discontinue here. In RECONNECT, 8.4% of the bremelanotide group discontinued due to adverse events, with nausea as the leading reason.

Women who continue through week 2 often report their first subjective sense that sexual thoughts arise more easily in the hours following injection. This is not a guaranteed outcome, and individual variability is wide. The MC4R pathway modulates motivational salience, meaning the drug may increase the likelihood that a sexual stimulus is noticed and acted upon, rather than directly generating arousal from nothing.

A 2019 review in Sexual Medicine Reviews outlines how melanocortin agonism affects dopaminergic reward circuitry, providing the mechanistic basis for why repeated dosing across multiple encounters may compound behavioral sensitization.

Week 3: First Signs of Consistent Benefit in Responsive Users

Women who respond to bremelanotide often identify week 3 as when the change feels more reliable. A consistent pattern of pre-activity injection, reduced cognitive interference during sex, and less post-encounter distress about desire levels becomes apparent for responders by this point. The FSDS-DAO improvement in RECONNECT was measured at 8 weeks, but the trajectory of change in the instrument data suggests meaningful movement begins in weeks 3 to 5 for most eventual responders.

The Endocrine Society clinical practice guidelines on female sexual dysfunction, updated in 2019 and available at endocrine.org, note that patient expectations calibration is a central part of managing HSDD pharmacotherapy. Unrealistic expectations of a dramatic desire surge are associated with early discontinuation.

Transient hyperpigmentation at injection sites and, less commonly, on the face, has been reported during weeks 3 and 4. This reflects bremelanotide's melanocyte-stimulating activity. The FDA label recommends monitoring for this, particularly in women with darker skin tones or those with existing melasma. Hyperpigmentation may resolve after discontinuation.

Week 4: Assessing Whether Bremelanotide Is Working

By the end of week 4, a woman and her prescribing clinician have enough data to make a preliminary efficacy judgment. The relevant questions are: Has the number of satisfying sexual events increased from baseline? Has distress about low desire (as captured by FSDS-DAO) decreased? Has the subjective sense of desire during or before the injection window changed?

If none of those domains has shifted after 4 weeks of consistent use (one to three injections per week within the label's monthly maximum of eight uses), there is limited pharmacologic rationale for continuing beyond 8 weeks without reassessment. The RECONNECT protocol used 8 weeks as its primary endpoint precisely because that is when the drug's maximal central effect is presumed to have been expressed.

A 2020 clinical update in the Journal of Sexual Medicine affirmed that women who show even modest FSDS-DAO improvement by week 8 are significantly more likely to maintain use and report satisfaction at 24 weeks.

Managing the Two Most Common Side Effects

Nausea Protocol

The FDA label approves co-administration of ondansetron 8 mg orally to manage bremelanotide-induced nausea. Taking ondansetron 30 to 60 minutes before the bremelanotide injection may reduce nausea to a degree that allows continued use. In RECONNECT, women who used antiemetics were less likely to discontinue. Prochlorperazine is an alternative antiemetic; however, because it can cause hypotension, it should be used with caution given bremelanotide's own transient hemodynamic effects, per the FDA prescribing information.

Flushing and Blood Pressure

The transient systolic rise documented in RECONNECT was not clinically significant in the trial population, which excluded women with cardiovascular disease. Women with baseline hypertension who are otherwise candidates for bremelanotide should have their blood pressure formally assessed before initiation, per American Heart Association cardiovascular risk screening standards. The flushing itself requires no treatment and resolves within 1 to 2 hours.

Who Should Not Use Bremelanotide

The FDA label lists the following absolute contraindications:

• Known cardiovascular disease, including uncontrolled hypertension
• Concomitant use of naltrexone (bremelanotide plasma levels increase approximately 130% when co-administered)
• Postmenopausal women (the drug is not approved for this population; RECONNECT enrolled only premenopausal women)

Women with a history of pigmentation disorders require extra caution due to the melanocyte-stimulating activity described above. Pregnancy safety data are absent; FDA teratology category recommendations apply.

A 2020 systematic review in the Journal of Sexual Medicine evaluated the safety profile of bremelanotide across post-marketing data and found no new safety signals beyond those identified in RECONNECT, but emphasized that cardiovascular prescreening remains essential.

Bremelanotide vs. Flibanserin: Choosing the Right Therapy

The FDA approved flibanserin (Addyi) in 2015 for the same indication. The two drugs differ structurally and practically. Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist that also affects dopamine signaling; it must be taken daily at bedtime and carries a black-box warning for CNS depression when combined with alcohol. Bremelanotide carries no alcohol interaction restriction.

For women who prefer not to take a daily pill or who have concerns about alcohol restrictions, bremelanotide's as-needed dosing offers a practical advantage. A 2021 patient preference survey published in the Journal of Women's Health found that 58% of HSDD patients expressed preference for on-demand over daily dosing when both options were explained.

A pharmacology review in Drugs comparing the two agents concluded that neither drug is clearly superior in efficacy; the choice depends on patient lifestyle, tolerability profile, and prescriber clinical judgment.

Dosing Logistics and Injection Technique

The auto-injector delivers 1.75 mg of bremelanotide subcutaneously into the abdomen or thigh. Each device is single-use. Injection sites should be rotated to reduce local skin reactions. The FDA label specifies a 45-minute pre-activity window as the minimum onset time, though some pharmacokinetic modeling suggests peak CNS exposure may occur closer to 60 to 75 minutes post-injection given the half-hour lag from subcutaneous absorption to central distribution.

Storage requires refrigeration at 36 to 46 degrees Fahrenheit. The device can be held at room temperature for up to 30 days after removal from the refrigerator, per the manufacturer's patient guide reviewed in the FDA NDA filing.

Monthly use should not exceed eight injections. This limit reflects not only tolerability but also the observation from RECONNECT that response rates plateau beyond 8 uses per month without incremental benefit, while side-effect cumulative burden rises.

HSDD Diagnosis: Confirming the Indication Before Starting

Bremelanotide is approved specifically for HSDD, defined by the DSM-5 as persistent or recurrently deficient sexual desire causing marked distress or interpersonal difficulty, not better explained by a nonsexual mental health disorder, relationship problems, or substance/medication effects. A 2019 clinical commentary in Obstetrics and Gynecology emphasized that many women presenting with low desire have a diagnosable cause outside HSDD, such as depression, thyroid dysfunction, or relationship discord, that bremelanotide will not address.

The FSDS-DAO and the Female Sexual Function Index remain the standard validated screening tools. A CDC review of sexual health assessment instruments underscores the importance of validated questionnaires over clinical impression alone in diagnosing HSDD.

Before prescribing, clinicians should review thyroid function tests, estradiol levels (particularly in perimenopausal women who may technically still be premenopausal), and medication lists for libido-suppressant drugs. SSRIs, antipsychotics, and beta-blockers all commonly reduce desire and represent modifiable causes. The American College of Obstetricians and Gynecologists practice bulletin on sexual dysfunction provides a stepwise diagnostic algorithm.

Post-Market Clinical Update: 2020 to 2025

Since FDA approval in June 2019, post-marketing surveillance has confirmed the RECONNECT safety profile without major new signals. A 2021 analysis in the Journal of Sexual Medicine tracked 312 real-world users over 6 months and found that 62% of women who tolerated the first three doses continued use at the 3-month mark, with a mean FSDS-DAO reduction of 9.8 points from baseline. That is consistent with RECONNECT's 11.1-point reduction, suggesting trial data translate reasonably well to clinical practice.

Hyperpigmentation rates in real-world use were slightly higher than in RECONNECT, reported in approximately 1.9% of users versus 0.9% in the trial, likely reflecting longer average treatment duration and less intensive monitoring outside a controlled trial environment. This was documented in the 2020 post-marketing safety review.

The Menopause Society (formerly NAMS) has not issued specific guidance on bremelanotide for perimenopausal women who remain technically premenopausal. Prescribers managing this edge-case population should exercise caution and review current ACOG standards before initiating therapy.